SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VPHM - Viropharma Inc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CoffeePot who wrote (111)7/14/1999 7:13:00 PM
From: scaram(o)uche  Read Replies (5) of 2557
 
>> I would still like to know how VPHM's "molecule" compares with the likes of asprin or any other OTC medicine for that matter. <<

I can't answer that question. You're comparing very effective medications for the treatment of symptoms with a molecule that inhibits viral entry into cells.

Aspirin will not prevent a cold. Pleconaril may just do such. We'll see.

>> Reducing the length of the average cold
from 14 days to 11 is not a medical breakthrough....IMO <<

That simply reflects your lack of experience at intervening with a viral infection after the appearance of symptoms. I'm certain that everyone at FDA is aware that this drug has already saved lives, even if they must consider the reports as anecdotal.

Moreover, it's an irrelevant concern tonight. For tonight, you should be asking if a market cap of 220 million is out of line for a company with strong data, targeting viral meningitis.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News